Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The authors assessed the effects of switching from a conventional angiotensin II receptor blocker (ARB) to azilsartan on blood pressure (BP) and health-related quality of life (HR-QOL) in patients with uncontrolled hypertension. Key eligibility criteria were uncontrolled hypertension treated for ≥ 1 month with an ARB, excluding azilsartan, that did not reach the target BP. We recruited 147 patients (64 males and 83 females; mean ± standard deviation age 73 ± 15 years). Azilsartan reduced both systolic and diastolic BP significantly, from 151 ± 16/82 ± 12 to 134 ± 17/73 ± 12 mm Hg, 3 months after switching. Although scores on the comprehensive QOL scale, the EuroQoL 5 dimensions (EQ5D), and the simplified menopausal index (SMI) did not change, the Geriatric Depression Scale (GDS) score improved significantly, and there was a significant association between the change in the GDS score and systolic BP lowering (r = 0.2554, P = 0.030). The Pittsburgh sleep quality index (PSQI) improved significantly only in the female subgroup. Besides sufficient BP lowering activity, anti-hypertensive treatment with azilsartan may have a favorable impact on depression in geriatric patients with uncontrolled hypertension.

Citation

Nobuharu Fujiwara, Atsushi Tanaka, Atsushi Kawaguchi, Motoko Tago, Jun-Ichi Oyama, Yasufumi Uchida, Kazuo Matsunaga, Kazuo Moroe, Shigeru Toyoda, Teruo Inoue, Hideo Ikeda, Koichi Node, APEQ Study Investigators. Association Between Blood Pressure Lowering and Quality of Life by Treatment of Azilsartan. International heart journal. 2017 Oct 21;58(5):752-761

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 28966324

View Full Text